Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07081022
PHASE2

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

View on ClinicalTrials.gov

Summary

To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

180

Start Date

2025-08-17

Completion Date

2027-04-06

Last Updated

2025-08-21

Healthy Volunteers

No

Interventions

DRUG

JS203 in combination with gemcitabine and oxaliplatin

Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days/cycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.

DRUG

JS203 in combination with ifosfamide, carboplatin and etoposide

Ifosfamide, carboplatin and etoposide, 3 cycles (Q3W) and JS203, Cycle 1 QW, Cycle 2 and therafter Q3W until trasnplant, progression or unacceptable toxicity.

DRUG

JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 6 cycles (Q3W) and JS203, 8 cycles (21 days/cycle), Cycle 1 QW, Cycle 2 to Cycle 8 Q3W.

DRUG

JS203 combined with lenalidomide

lenalidomide,12 cycles, Cycle 1(Q3W), Cycle 2 to Cycle 12 (Q4W) and JS203, 12 cycles, Cycle 1 (21 days/cycle) QW, Cycle 2 to Cycle 12 (28 days/cycle) Q4W.

Locations (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China